Tag Archives: alks 8700

November, 2017

27 November
Biogen and Alkermes Partner to Develop and Commercialize Multiple Sclerosis Drug ALKS 8700

CAMBRIDGE, Mass. & DUBLIN–(BUSINESS WIRE)–Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate (MMF) small drug molecule in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (MS). “This …
Share

9 February
Alkermes’ Reformulated Tecfidera Shows Fewer Side Effects in Early-Stage Study

Dublin-based Alkermes plc announced positive results from an early-stage stage study, evaluating its novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis (MS). The company announced positive topline results from a Phase I study of ALKS 8700, the company’s reformulated version of Biogen Idec’s blockbuster MS …
Share